Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications

Current Psychiatry Reports

Volumn 13, Issue 5, 2011, Pages 357-363

  Hammerness, Paul G ^a   Surman, Craig B H ^a   Chilton, Ashley ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

ADHD; Adult.medication; Cardiovascular; Stimulant; Treatment

Indexed keywords

AMPHETAMINE; ATOMOXETINE; DEXMETHYLPHENIDATE; LISDEXAMFETAMINE; METHYLPHENIDATE; PLACEBO;

ARTICLE; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; CONSTIPATION; DECREASED APPETITE; DIASTOLIC BLOOD PRESSURE; DROWSINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERECTILE DYSFUNCTION; HEADACHE; HEART CONDUCTION; HEART PALPITATION; HEART RATE; HUMAN; HYPERTENSION; INSOMNIA; NAUSEA; PAIN; QT PROLONGATION; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT OUTCOME; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ADULT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM STIMULANTS; CLINICAL TRIALS AS TOPIC; HEART RATE; HUMANS;

EID: 80755140042     PISSN: 15233812     EISSN: 15351645     Source Type: Journal    
DOI: 10.1007/s11920-011-0213-3     Document Type: Article

References (50)

1. Fayyad J, de Graaf R, Kessler R, et al. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry. 2007;190:402-9. (Pubitemid 46706952)
2. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-23. (Pubitemid 44464584)
3. Birnbaum HG, Kessler RC, Lowe SW et al. Costs of ADHD in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin. 2005;21(2):195-206.
4. Kessler RC, Lane M, Stang PE, et al. The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm. Psychol Med. 2008;21:1-11.
5. de Graaf R, Kessler RC, Fayyad J, et al. The prevalence and effects of adult ADHD on the performance of workers: results from the WHO World Mental Health Survery Initiative. Occup Environ Med. 2008;65(12):835-42.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th Edn Text Revision (DSM-IV-TR). 4th ed. Washington, DC: American Psychiatric Association. 2000.
7. Kessler RC, Adler L, Ames M, et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35:245-56. (Pubitemid 40259916)
8. Kessler RC, Adler LA, Gruber MJ, et al. Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members. Int J Methods Psychiatr Res. 2007;16(2):52-65. (Pubitemid 46930456)
9. Faraone SV, Biederman J, Spencer T, et al. Diagnosing adult attention deficit hyperactivity disorder: are late onset and subthreshold diagnoses valid? Am J Psychiatry. 2006;163(10):1720-9. (Pubitemid 44522480)
10. Plizka S. AACAP practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921.
11. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult ADHD using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71(6):754-63.
12. Wood DR, Reimherr FW, Wender PH, Johnson GE. Diagnosis and treatment of minimal brain dysfunction in adults: a preliminary report. Arch Gen Psychiatry. 1976;33(12):1453-60. (Pubitemid 8005003)
13. • CADDRA Canadian ADHD Practice Guidelines. Available at http://www.caddra.ca/cms4/. Accessed April 2011. This up-to-date guideline is available for download. It provides detailed information on the assessment of ADHD in adults and presents a very comprehensive approach to treatment.
14. Gibbins C, Weiss M. Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults. Curr Psychiatry Rep. 2007;9(5):420-6. (Pubitemid 47565024)
15. •• Perrin JM, Friedman RA, Knilans TK: Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 2008, 122:451-453. This is an important position report from the American Academy of Pediatrics on the cardiovascular risk of stimulant medications in pediatric ADHD.
16. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with ADHD: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol. 2009;29(3):239-47.
17. Rösler M, Fischer R, Ammer R, et al. A randomised, placebocontrolled, 24-week, study of low-dose extended-release methylphenidate in adults with ADHD. Eur Arch Psychiatry Clin Neurosci. 2009;259(2):120-9.
18. Biederman J, Mick E, Surman C, et al. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmoticrelease oral system-methylphenidate in adults with ADHD. J Clin Psychopharmacol. 2010;30(5):549-53.
19. Bejerot S, Rydén EM, Arlinde CM. Two-year outcome of treatment with central stimulant medication in adult ADHD: a prospective study. J Clin Psychiatry. 2010;71(12):1590-7.
20. Adler LD, Nierenberg AA. Review of medication adherence in children and adults with ADHD. PostgradMed. 2010;122(1):184-91.
21. Spencer TJ, Mick E, Surman CB, et al. A randomized, singleblind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. J Atten Disord. 2011;15(4):286-94.
22. Ginsberg L, Katic A, Adeyi B, et al. Long-term treatment outcomes with lisdexamfetamine dimesylate for adults with ADHD stratified by baseline severity. Curr Med Res Opin. 2011;27(6):1097-107.
23. Biederman J, Mick E, Fried R, et al. Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD. Eur Neuropsychopharmacol. 2011 Mar. 8 (Epub ahead of print).
24. Barkley RA, Fischer M. Predicting impairment in major life activities and occupational functioning in hyperactive children as adults: self-reported executive function (EF) deficits versus EF tests. Dev Neuropsychol. 2011;36(2):137-61.
25. Brown TE, Brams M, Gao J, et al. Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of ADHD in adults. Postgrad Med. 2010;122(5):7-17.
26. Adler L, Dietrich A, Reimherr FW, et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann Clin Psychiatry. 2006;18(2):7-13.
27. Michelson D, Adler LA, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112-20. (Pubitemid 36126473)
28. Adler LA, Spencer TJ, Williams DW, et al. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Atten Disord. 2008;12(3):248-53.
29. Surman CB et al. Representativeness of participants in a clinical trial for ADHD? Comparison with adults from a large observational study. J Clin Psychiatry. 2010;71(12):1612-6.
30. Durell T, Adler L, Wilens T, et al. Atomoxetine treatment for ADHD: younger adults compared with older adults. J Atten Disord. 2010;13(4):401-6.
31. Marchant BK, Reimherr FW, Halls C, et al. Long-term open-label response to atomoxetine in adult ADHD: influence of sex, emotional dysregulation, and double-blind response to atomoxetine. Atten Defic Hyperact Disord. 2011 Mar. 27 (Epub ahead of print).
32. Brown TE, Holdnack J, Saylor K, et al. Effect of atomoxetine on executive function impairments in adults with ADHD. J Atten Disord. 2011;15(2):130-8.
33. Young JL, Sarkis E, Qiao M, Wietecha L. Once-daily treatment with atomoxetine in adults with ADHD: a 24-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2011;34(2):51-60.
34. Biederman J, Mick E, Surman C, et al. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with ADHD. BMC Psychiatry. 2007;7(1):49.
35. Medori R, Ramos-Quiroga JA, Casas M, et al. A randomized, placebo-controlled trial of three fixed dosages of prolongedrelease OROS methylphenidate in adults with ADHD. Biol Psychiatry. 2008;63(10):981-9.
36. Spencer TJ, Adler LA, McGough JJ, et al. Efficacy and safety of dexmethylphenidate extended-release capsules in adults with ADHD. Biol Psychiatry. 2007;61(12):1380-7. (Pubitemid 46855767)
37. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with ADHD. J Clin Psychiatry. 2005;66(2):253-9. (Pubitemid 40314334)
38. Weisler RH, Biederman J, Spencer TJ, Wilens TE. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 SUPPL. 20):35-43. (Pubitemid 43010496)
39. Adler LA, Weisler RH, Goodman DW, et al. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with ADHD. J Clin Psychiatry. 2009;70(12):1652-61.
40. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003;26(10):729-40. (Pubitemid 36976134)
41. Nissen S. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354(14):1445-8.
42. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medication for ADHD: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117(8):2407-23. (Pubitemid 351653546)
43. Villalba L, Racoosin J. Postmarketing safety review of sudden death during treatment with drugs used to treat ADHD. Food Drug Admin. Feb. 28, 2006.
44. Winterstein AG, Gerhard T, Shuster J, Saidi A. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics. 2009;124(1):75-80.
45. AHRQ website. Available at http://www.ahrq.gov/. Accessed April 27, 2011.
46. FDA website. Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/Drug SafetyInformationforHeathcareProfessionals/ucm165858.htm. Accessed May 24, 2011.
47. Cooney MT, Vartiainen E, Laatikainen T, et al. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J. 2010;159(4):612-9.
48. Fox K, Borer JS, Camm AJ, Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50(9):823-30. (Pubitemid 47277500)
49. Gerhard T, Winterstein AG, Olfson M, et al. Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD. Pharmacoepidemiol Drug Saf. 2010;19(5):457-64.
50. Hammerness P, Zusman R, Systrom D, Surman C et al. An indepth cardiovascular study of lisdexamfetamine (ldx) in adults with ADHD. Poster presentation; American Psychiatric Association Annual Meeting, May 22-26, 2010, New Orleans, LA.